SELLAS Life Sciences
18 hedge funds and large institutions have $1.6M invested in SELLAS Life Sciences in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
11% more capital invested
Capital invested by funds: $1.45M → $1.6M (+$152K)
6% more funds holding
Funds holding: 17 → 18 (+1)
0.91% less ownership
Funds ownership: 1.02% → 0.12% (-0.91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.11M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$154K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.8K |
| 4 |
Jane Street
New York
|
+$12.3K |
| 5 |
MML Investors Services
Springfield,
Massachusetts
|
+$9.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$442K |
| 2 |
Renaissance Technologies
New York
|
-$426K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$82K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$52K |
| 5 |
6CM
683 Capital Management
New York
|
-$47.9K |
SLS Hedge Fund Activity: Q3 2019 in Review
18 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2019, worth a combined $1.6M — up 11% from $1.45M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SLS positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.11M. The largest seller was Sabby Management, exiting entirely with an estimated $442K sold.
- 18 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2019, up from 17 in Q2 2019.
- Funds reported $1.6M of SELLAS Life Sciences stock for Q3 2019, up 11% quarter-over-quarter.
- 7 funds opened new SELLAS Life Sciences positions in Q3 2019 and 6 closed out, a net change of +1 holder.
- The largest SELLAS Life Sciences buyer in Q3 2019 was Vanguard Group, an estimated $1.11M added.
- The largest SELLAS Life Sciences seller in Q3 2019 was Sabby Management, an estimated $442K sold.
Based on aggregated 13F filings for Q3 2019.